Drug Trial Radar · NCT05284617
Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF
Last checked: Nov 19, 2026Latest source record: Aug 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
67
Actual
Start
Oct 30, 2022
Primary completion
May 24, 2024
Study completion May 30, 2024
Sponsor
- Lead sponsor
- Rivus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 2A, randomized, parallel-group, placebo-controlled, double-blind, within subject dose escalation trial with 3 dose levels of HU6 and placebo. Subjects will be randomized (1:1) either to HU6 or placebo. Two dose levels will be administered in sequential order (150 mg daily followed by 300 mg daily), each for 20 days, to reach the third and highest dose of 450 mg daily if safety and tolerability are demonstrated at the lower 2 preceding doses. Administration of the 450 mg high dose will continue for a total of 94 days, with a safety follow-up visit within \~14 days of the last dose.
Conditions
- Heart Failure With Preserved Ejection Fraction
Interventions
HU6Drug
HU6 is being evaluated for its efficacy in improving cardiovascular function in obese subjects with HF with preserved ejection fraction (HFpEF).
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate weight reduction while on HU6 treatmentTime frame: 5 months
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
National Heart Institute
Beverly Hills, California
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center
Torrance, California
New Generation of Medical Research
Hialeah, Florida
Broward Research Center
Pembroke Pines, Florida
Northwestern University
Chicago, Illinois
The University of Chicago Medical Center
Chicago, Illinois
Johns Hopkins University
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Mayo Clinic
Rochester, Minnesota
Saint Luke's Mid America Heart Institute
Kansas City, Missouri
Weill Cornell Medicine
New York, New York
Wake Forest
Winston-Salem, North Carolina
The Lindner Center for Research and Education at The Christ Hospital
Cincinnati, Ohio
Medical University of South Carolina
Charleston, South Carolina
University of Texas Southwestern
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.